跳至主要内容
临床试验/NCT01051778
NCT01051778已完成2 期

Low-molecular-weight Heparin Versus Unfractionated Heparin in Pregnant Women With History of Recurrent Abortion Secondary to Antiphospholipid Syndrome. A Randomized Controlled Trial

Cairo University2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2006年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
入组人数
60
试验地点
2
主要终点
Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)

研究概览

简要总结

The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with antiphospholipid syndrome (APS).

详细描述

Women with antiphospholipid syndrome (APS) have live birth rates as low as 10% in pregnancies without pharmacological treatment. Low dose aspirin (LDA) ,unfractionated heparin(UFH) , Low molecular weight heparin (LMWH) , prednisone, and intravenous immunoglobulin (IVIG) have been used either alone or in combination in order to improve the live birth rate in APS positive women with recurrent miscarriage. A Cochrane review of 13 randomized or quasi-randomized, controlled trials of various management options of pregnant women with a history of pregnancy loss and APL, revealed that combined UFH and aspirin was the treatment of choice which reduced pregnancy loss by 54% .

During the past decade , low molecular weight heparins were widely used in the prophylaxis and treatment of patients with venous or arterial thrombosis ,with an efficacy and safety superior or at least equivalent to that of UFH .Although recent studies reported the use of LMWH in the management of patients recurrent pregnancy loss secondary to antiphospholipid syndrome resulted in encouraging results . It is not clear whether the efficacy and safety of LMWH is equivalent to that of UFH .

Although LMWH is more expensive than UFH . LMWH has longer half life , greater bioavailability , more stable dose-response relationship than UFH and therefore can be administered once daily. Furthermore, LMWH requires less frequent monitoring than UFH and and has less adverse effect on bone mineral density and platelet count .These advantages make LMWH more attractive for the patients and physicians than UFH .

There are only two studies which compared the efficacy of LMWH plus LDA with that of UFH plus LDA in the management of pregnant women with recurrent pregnancy loss secondary to APS. In addition ,no randomized controlled study has yet compared the efficacy of LMWH plus LDA with UFH plus LDA.

The aim of this study is to compare the efficacy and safety of Low molecular weight heparin (LMWH) plus low dose aspirin (LDA) with unfractionated heparin(UFH) plus LDA in women with recurrent pregnancy loss associated with antiphospholipid syndrome (APS).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
19 Years 至 37 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Patients with a minimum of three consecutive pregnancy losses before 10 weeks gestation
  • Positive lupus anticoagulant and/or anticardiolipin antibodies (IgG and IgM) on at least two occasions twelve weeks apart .
  • Age between 19 - 37 years,
  • Body mass index between 19-30

排除标准

  • Parental chromosomal abnormalities
  • Uterine abnormalities
  • Luteal phase defect
  • Systemic lupus erythematosus
  • Previous thromboembolism
  • Sensitivity to aspirin.

研究组 & 干预措施

enoxaparin 40 mg plus low dose aspirin

Experimental

干预措施: enoxaparin 40mg plus low dose aspirin (Drug)

Heparin calcium 5,000 U twice daily plus low dose aspirin

Active Comparator

干预措施: Heparin calcium5,000 U twice daily plus low dose aspirin (Drug)

结局指标

主要结局

Live Birth Rate = (Number of Live Births / Total Number of Pregnancies)

时间窗: pregnancy > 24weeks gestation

Live birth occurs when a fetus (\> 24 weeks ) , exits the maternal body and subsequently shows signs of life, such as voluntary movement, heartbeat, or pulsation of the umbilical cord.

次要结局

  • Preterm Delivery(24 weeks gestation<Pregnancy <37weeks gestation)
  • Minor and Major Bleeding(Duration of pregnancy and puerperium)
  • Thrombocytopenia(Duration of pregnancy and puerperium)
  • IUFD(Pregnancy >24 weeks gestation)
  • Preeclampsia(Pregnancy > 20 weeks gestation)
  • Spontaneous Osteoporotic Fractures(Duration of pregnancy and puerperium)

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验